Successful management of late-onset Streptococcus mitis endophthalmitis
Received 14 August 2017
Accepted for publication 28 September 2017
Published 17 October 2017 Volume 2017:13 Pages 1439—1442
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Garry Walsh
Jinmann Chon,1 Moosang Kim2
1Department of Rehabilitation Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, 2Department of Ophthalmology, School of Medcine, Kangwon National University, Chuncheon, Korea
Abstract: Endophthalmitis following intraocular surgery can be devastating. This case report demonstrates successful management of late-onset Streptococcus mitis endophthalmitis treated by vitrectomy, panretinal photocoagulation (PRP) and silicone oil tamponade. A 75-year-old man presented with painful vision loss in his right eye. The patient had uneventful phacoemulsification and intraocular lens implantation in the right eye at an outside clinic 6 weeks prior. Examination disclosed hypopyon and vitritis, as well as discrete inflammatory collections in the vitreous. The patient underwent vitrectomy with PRP and silicone oil tamponade. Vitreous cultures were positive for S. mitis, a pathogen associated with severe tissue damage and poor clinical outcomes. One month after the surgery, intraocular inflammation was stabilized, and visual acuity was improved from light perception to 20/200. Aggressive surgical management may play a role in improving outcomes in these patients.
Keywords: late-onset endophthalmitis, Streptococcus mitis, vitrectomy
Endophthalmitis following intraocular surgery can be devastating. The visual loss and debilitation that occur in a large proportion of postoperative endophthalmitis cases can be severe and irreversible. Outcomes for cases of endophthalmitis involving oral Streptococcal species are notoriously poor; even with timely therapy, final visual acuity of <20/400 occurs in up to 50%–80% of these cases, with many cases requiring evisceration or enucleation.1–3 Presumably, there are other pathogenic mechanisms at work that are not addressed by intravitreal antibiotics alone, and a more aggressive therapeutic approach may be warranted. We describe successful management of a case of late-onset (6 weeks) Streptococcus mitis endophthalmitis after uncomplicated cataract surgery was treated promptly with vitrectomy, panretinal photocoagulation (PRP) and silicone oil tamponade.
A 75-year-old man was referred to our hospital for severe pain and decreased visual acuity started 1 day ago in the right eye. Six weeks prior to this, the patient had uneventful phacoemulsification and intraocular lens (IOL) implantation in the right eye at an outside clinic. On examination, the best-corrected visual acuity (BCVA) was light perception in the right eye. Slit-lamp biomicroscopy of the eye showed severe conjunctival injection, corneal edema, corneal infiltration at superior main incision, membrane formation around the IOL and a deep anterior chamber with a 2 mm hypopyon, which were thought to represent infectious endophthalmitis (Figure 1). There was no view of the fundus in his right eye. B-scan ultrasonography demonstrated significant vitreous opacities (Figure 2). A diagnosis of acute postcataract surgery endophthalmitis was made.
Figure 1 Right eye shows conjunctival injection, corneal edema with infiltrates at the superior corneal incision site, membrane formation around the IOL and a 2 mm hypopyon.
Figure 2 B-scan ultrasound of the right eye shows a significant amount of vitreous debris.
Given the severity of the patient’s presentation and with the presence of severe vitreous opacities, the patient underwent a 23-gage transconjunctival sutureless vitrectomy using the Dutch Ophthalmic Research Center two-step reusable system (DORC; Zuidland, the Netherlands). The cannula was inserted at a 10°–30° angle through the conjunctiva, sclera and pars plana 3.5 mm from the limbus. The cannulas were placed in the inferotemporal, superotemporal and superonasal quadrants. An illumination probe was placed at the superonasal quadrant, and a 23-gage infusion cannula was placed at the inferotemporal quadrant. A noncontact Biom indirect viewing system (Oculus Inc., Petaluma, CA, USA) was used for the visualization of the posterior segment. Vitrectomy was performed using a 23-gage high-speed vitrector with a cut rate of 2,500/minute. The vitrectomy involved complete removal of the posterior vitreous till the vitreous base. During the vitrectomy, we saw severe vitreous opacities and a thick exudative membrane that covered the entire retina (Figure 3A). After delicate vitrectomy-like shaving, we could see the disk and major vessel arcade faintly. Retinal hemorrhages were noted in all quadrants (Figure 3B). Because retina appears pale, we performed PRP. After PRP, fluid–air exchange and then silicone oil injection were performed.
Figure 3 Intraoperative view during vitrectomy.
Improvement of pain was noted on postoperative day 1, and the patient was started on a regimen of ophthalmic drops that included fortified vancomycin (50 mg/mL) and amikacin (20 mg/mL), prednisolone 1%, and homatropine 2%, as well as systemic antibiotics (flomoxef 1.0 g every 12 hours). Vitreous specimens obtained during vitrectomy were found to be positive for S. mitis (Figure 4). On blood agar, Gram-positive cocci 0.6–0.8 μm in diameter, arranged in pairs or chains, nonmotile colonies were seen after 2 days of incubation. The isolate was susceptible to amikacin, methicillin, ceftriaxone, moxifloxacin and vancomycin.
Figure 4 Culture of aspirated vitreous fluid shows growth of Streptococcus mitis (culture media: blood agar).
On postoperative day 7, BCVA improved to 20/400, and slit-lamp biomicroscopy showed moderate inflammatory reaction without hypopyon and decreased inflammatory membrane on the IOL. During 1 month of postoperative follow-up, the patient’s right-eye BCVA gradually improved to the range of 20/200 to light perception, and the patient remained stable without pain or ocular discomfort. Fundus examination revealed an attached retina with resolving vitreous haziness, complete silicone oil fill and 360° PRP marking (Figure 5).
Figure 5 Wide-field fundus photography of the right eye postoperatively demonstrates an attached retina under silicone oil tamponade and full panretinal photocoagulation treatment to all quadrants.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
S. mitis is an α-hemolytic Gram-positive coccus of the viridians streptococcus group and is commonly found in the oropharynx, respiratory tract, female genital tract and gastrointestinal tract. Although considered to have low virulence and pathogenicity, it may cause life-threatening infections, particularly endocarditis and meningitis.4 S. mitis is rarely found as normal conjunctival commensal. Possible sources of contamination include contamination of the needle or the patient’s conjunctiva with S. mitis during the procedure itself or even while talking between the patient, surgeon and other staff.5 Recently, endophthalmitis outbreak of S. mitis after intravitreal injection of bevacizumab has been reported, and contamination during syringe preparation of compounding pharmacy was found as the cause, which implies that microbial contamination could occur at any step of preparation or surgical procedures.6 The source of infection in our patient remains doubtful as our patient developed late-onset endophthalmitis (6 weeks following cataract surgery). The patient presented within 12 hours from onset of symptoms and responded well to immediate vitrectomy with PRP and silicone oil tamponade in spite of severe inflammation.
The Endophthalmitis Vitrectomy Study (EVS), published in 1995, was a prospective, randomized and multicenter clinical trial that evaluated the roles of pars plana vitrectomy and systemic antibiotics for the management of acute-onset endophthalmitis following cataract surgery or secondary IOL implantation in 420 patients.7 Between the immediate vitrectomy and intravitreal injection of antibiotics-only subgroups, there was a threefold increase in the frequency of achieving 20/40 or better, nearly a twofold chance of achieving 20/100 visual acuity or better and a 50% decrease in the frequency of severe visual loss (defined as visual acuity worse than 5/200) in those who presented with an initial vision of light perception only and who underwent an immediate vitrectomy. The EVS represented large-gage vitrectomy, and its results may not be applicable to the small-gage vitrectomy widely performed today. We believe that, in the era of small-gage vitrectomy, immediate vitrectomy for endophthalmitis may be of significant benefit in removing infectious material and vitreous debris, which are paramount, respectively, for accelerating infection clearance and optimizing visual outcomes.
Chung and Sung8 reported excellent outcome in a case of S. mitis endophthalmitis after complicated iris-fixated phakic IOL implantation treated with intravitreal antibiotic injection as there was no vitreous involvement. However, the S. mitis endophthalmitis after intravitreal injections and intraocular surgeries has been reported with devastating visual outcomes in majority of patients.5,9–11 Taken together, the virulence and pathogenicity seem to be different on the tissue-by-tissue or organ-by-organ basis.8
Late-onset postoperative S. mitis endophthalmitis has not yet been reported to the best of our knowledge. Our report illustrates that late-onset S. mitis endophthalmitis can develop in patients who underwent uncomplicated cataract surgery, and it can be managed with early vitrectomy, PRP and silicone oil tamponade.
Endophthalmitis caused by exotoxin-producing bacterial species such as S. mitis is often associated with severe vision loss or loss of the eye. Aggressive surgical management may play a role in improving outcomes in these patients.
This study was supported by 2017 Kangwon National University Hospital Grant.
The authors report no conflicts of interest in this work.
Kuriyan AE, Weiss KD, Flynn HW Jr, et al. Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes. Am J Ophthalmol. 2014;157(4):774–780.
Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six year experience at a university referral center. Retina. 2011;31:662–668.
Miller JM, Scott IU, Flynn HW Jr, Smiddy WE, Corey RP, Miller D. Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol. 2004;138(2):231–236.
Kutlu SS, Sacar S, Cevahir N, Turgut H. Community-acquired Streptococcus mitis meningitis: a case report. Int J Infect Dis. 2008;12(6):107–109.
Chen E, Lin MY. Endophthalmitis after intravitreal injection. The importance of viridans streptococci. Retina. 2011;31:1525–1533.
Goldberg RA, Flynn HW Jr, Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):204–208.
Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479–1496.
Chung JK, Sung JL. Streptococcus mitis/oralis endophthalmitis management without phakic intraocular lens removal in patient with iris-fixated phakic intraocular lens implantation. BMC Ophthalmol. 2014;14:92.
Chen E, Ho AC, Garg SJ, Brown GC, Kaiser RS. Streptococcus mitis endophthalmitis presenting as frosted branch angiitis after intravitreal pegaptanib sodium injection. Ophthalmic Surg Lasers Imaging. 2009;40(2):192–194.
Matthews JL, Dubovy SR, Goldberg RA, Flynn HW Jr. Histopathology of Streptococcus mitis/oralis endophthalmitis after intravitreal injection with bevacizumab: a report of 7 patients. Ophthalmology. 2014;121(3):702–708.
Mao LK, Flynn HW Jr, Miller D, Pflugfelder SC. Endophthalmitis caused by streptococcal species. Arch Ophthalmol. 1992;110(6):798–801.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.